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ABSTRACT
Background: South Africa, as an emerging middle-income country, is becoming increasingly
influential in global health diplomacy (GHD). However, little empirical research has been
conducted to inform arguments for the integration of domestic health into foreign policy by
state and non-state actors. This study seeks to address this knowledge gap. It takes the form
of an empirical case study which analyses how South Africa integrates domestic health into
its foreign policy, using the lens of access to antiretroviral (ARV) medicines.
Objective: To explore state and non-state actors’ perceptions regarding how domestic health
policy is integrated into foreign policy. The ultimate goal of this study was to achieve better
insights into the health and foreign policy processes at the national level.
Methods: Employing qualitative approaches, we examined changes in the South African and
global AIDS policy environment. Purposive sampling was used to select key informants, a
sample of state and non-state actors who participated in in-depth interviews. Secondary data
were collected through a systematic literature review of documents retrieved from five
electronic databases, including review of key policy documents. Qualitative data were ana-
lysed for content. This content was coded, and the codes were collated into tentative
categories and sub-categories using Atlas.ti v.7 software.
Results: The findings of this work illustrate the interplay among social, political, economic
and institutional conditions in determining the success of this integration process. Our study
shows that a series of national and external developments, stakeholders, and advocacy efforts
and collaboration created these integrative processes. South Africa’s domestic HIV/AIDS
constituencies, in partnership with the global advocacy movement, catalysed the mobiliza-
tion of support for universal access to ARV treatment nationally and globally, and the
promotion of access to healthcare as a human right.
Conclusions: Transnational networks may influence government’s decision making by pro-
viding information and moving issues up the agenda.
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Background
Health policy has changed in the twenty-first century
as a result of globalization and the higher priority of
health in international political agendas [1–3].
Recognizing the close, interdependent relationship
between foreign policy and global health, the foreign
ministers of seven countries issued the Oslo
Ministerial Declaration, entitled ‘Global health – a
pressing foreign policy issue of our time’ [4].
Subsequently, the United Nations General Assembly
(UNGA) adopted several resolutions on health and
foreign policy. Furthermore, a number of countries,
such as the USA, the UK and Norway, launched their
national global health strategies to explore how for-
eign policy could contribute towards tackling impor-
tant health issues and how a health dimension could
benefit foreign policy. Within this context, the term
global health diplomacy (GHD) has emerged to
describe the political processes that states and non-
states use to negotiate about health-related foreign
policy issues [5]. Furthermore, looking back over
the past 15 years, there has been an increase in the
number of actors, processes and initiatives that
acknowledge and reflect both the diversity of global
power and the need to act together [6]. The north–
south divide has changed through undertaking joint
but differential responsibilities. In addition, innova-
tive development finance is gaining ground over
development aid and there is a renewed commitment
to common goals, as reflected in the Sustainable
Development Goals (SDGs). The creation of new
transnational collaborations between India, Brazil
and South Africa (IBSA), and between Brazil,
Russia, India, China and South Africa (BRICS), has
led to power shifts in political and economic decision
making and is transforming international health poli-
cies [7].
Therefore, from a public health perspective, it is
important to understand how the proliferation of
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actors, processes, new institutions and initiatives will
shape global health governance, its approaches and its
values [8]. The main challenge for governments and
non-state organizations is in developing a multisec-
toral and coherent approach to overcome fragmented
policy coherence [9].
In light of these challenges, several commentators
have tried to introduce a structure to analyse the global
health policymaking process. However, many scholars
have argued that no single framework offers a fully
comprehensive description or understanding of the
policymaking process, as each framework answers
somewhat different questions. The lack of agreed-
upon theoretical and analytical frameworks for GHD
means that the current GHD literature is fairly frag-
mented, and not clearly structured around key research
problems or questions [10]. In this article, we use
Kingdon’s Multiple Streams Model to explain how a
national public health issue is integrated into foreign
policy agendas, in particular, access to antiretroviral
(ARV) medicines in South Africa [11,12]. While the
Kingdon Model contains useful elements, it does not
include enough detail on the problem/agenda-setting
process, nor does it monitor the quality of policy
implementation or measure policy impact. As such, in
this article, we use the adapted Walt and Gilson’s
(1994) policy analysis triangle as a heuristic device to
gather and organize a comprehensive and relevant set
of data in five areas [13,14]. A fifth important category
has been added by Gagnon and Labonté (2013) to
capture data that reveal the potential and actual effects
of a policy [13]. These frameworks are not exclusive or
theoretically or analytically distinct, but are used
together as a useful and novel mechanism by which
to analyse and interpret the research findings.
In this article, we focus on the domestic public health
policy on access to ARV medicines in South Africa.
Access to ARVs was chosen pragmatically as South
Africa currently has the largest number of people living
with human immunodeficiency virus (HIV) globally.
An estimated 6.8 million people are living with HIV,
of whom around 3.1 million are currently receiving
antiretroviral treatment (ART) [15]. Therefore, this arti-
cle looks at how a policymaking process is undertaken
to integrate domestic public health policy into foreign
policy in South Africa, using the lens of access to ARV
medicines. The ultimate goal of this study is to achieve
better insights into the health and foreign policy pro-
cesses at the national level.
Methods
We used a case-study design that included a systema-
tic literature review (of both peer-reviewed and grey
literature), analysis of official policy documents and
in-depth interviews with key GHD actors. We first
conducted a systematic review of literature for South
Africa between May 2014 and December 2015. We
expanded our search to include literature between
2000 and 2015 because GHD is a relatively new
phenomenon which saw the launch of the Oslo
Declaration as a commitment to advancing health
and well-being on a global scale. We limited our
search to studies written in English.
We used search engines such as Academic Africa-
Wide Information, Academic Search Premier,
CINAHL and MEDLINE to find literature. We used
the key words ‘global health’, ‘diplomacy’, ‘foreign
affairs’, ‘global health diplomacy,’ ‘medicines’ and ‘anti-
retroviral medicines’ (Figure 1). In this article, we
focused on South Africa’s GHD policy for access to
ARV medicines. As a further check, we conducted six
searches using Google Scholar on title and/or abstract,
with screening stopping on the tenth page/article which
signifies the tenth redundant article in a row.
We manually searched the following key journals in
the past year: Health Policy & Planning, World Health
Organization Bulletin, The Lancet, Globalization and
Health, Health Policy and Global Health Governance.
Reference lists of relevant articles, related systematic
reviews and key author searches were conducted.
Articles were excluded if they had a domestic analysis,
reported global epidemiological data, did not focus on
health or were summary reports. A final collection of
20 peer-reviewed articles and 25 grey literature articles
constituted the data set on which the analysis of this
article is based.
Official policy documents relevant to primary
cases, South Africa, were reviewed and their content
categorized systematically using Walt and Gilson’s
heuristic categories [14]. Documents were analysed
in terms of their content value and their historical
value. All the documents were screened for relevant
content. A total of 26 key documents (of which 14
were published policy documents) were used for
analysis.
Both SMM and SJHH conducted an independent
full-text review of all the articles and policy docu-
ments using pre-existing data extraction forms.
Disagreements that occurred during the application
of the exclusion criteria or data extraction were nego-
tiated until consensus was reached.
We used purposeful sampling [16] to identify and
recruit interviewees based on relevant peer-reviewed
or grey literature. Interviewees had to have extensive
professional networks in global health and develop-
ment. Additional interviewees were enrolled using
snowball sampling until no new concepts emerged.
Respondents came from state, non-state and intergo-
vernmental organizations. We conducted 21 inter-
views, drawn from state and non-state actors with
extensive experience (i.e. more than 10 years’ worth)
and skills related to GHD, and those involved in the
international negotiations for improved access to
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ARV medicines, as outlined in Table 1. Interviews
were conducted between November 2015 and April
2016. All 13 South African interviewees were person-
ally interviewed at convenient times by the lead
researcher. Eight international interviewees were
interviewed by telephone, via Skype and during the
margins of regional and global health events, includ-
ing the United Nations (UN) High Level Panel on
access to medicines in Johannesburg, South Africa,
March 2016, and the East, Central and Southern
African-Health Community, held in Nairobi, Kenya,
April 2016. The interviews lasted for about 45 minutes
to 1 hour. Interviewees were recruited using the
recruitment letter. Informed consent was obtained
before the interviews began. All interviews were
tape-recorded and transcribed verbatim.
Data collection and analysis were done concur-
rently, resulting in continuous interpretations and
preliminary reports. Data were analysed for content,
coded, and subsequently collated into tentative sub-
categories and categories using software Atlas.ti
Scientific Software, v.7 [16,17]. Data analysis was
continuously discussed by SMM and SJHH to ensure
constant comparison of the sub-categories and cate-
gories with the original text. To preserve anonymity,
names and affiliations are not released. Ethical
approval was obtained from the University of
Pretoria’s Ethics Committee.
Results
Context: health is a human right
In South Africa, the concept of health as a human
right is important in both national and international
Table 1. Characteristics of key informants from all cases
(n = 21).
Characteristics
Affiliation Government 9 (42)
NGO 1 (5)
Academia 3 (14)
Research 1 (5)
Think tank 2 (10)
Private sector 2 (10)
UN agency 3 (14)
Gender Male 12 (57)
Female 9 (43)
Rank Director and upwards 9 (42)
CEO 2 (10)
Scientist or researcher 2 (10)
Lecturer and upwards 3 (14)
Policy advisor or analyst 3 (14)
Diplomat 2 (10)
Cases Primary 13 (62)
Background 8 (38)
Data are shown as n (%).
NGO = non-governmental organization; UN = United Nations;
CEO = chief executive officer.
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Figure 1. Flow diagram of study selection for the systematic review of published research on global health diplomacy (GHD) in
South Africa. ARVs = antiretrovirals.
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policy [18–21]. The inclusion of health in the South
African constitution, which seeks to guarantee indi-
vidual rights, was supported by former President
Mandela, who argued that ‘issues of human rights
are central to international relations and an under-
standing that they extend beyond the political,
embracing the economic, social and environmen-
tal’ [22].
In 2007, South Africa participated in the formation
of the Global Health and Foreign Policy Initiative,
where the Oslo Ministerial Declaration identified
‘global health’ as ‘a pressing foreign policy issue of
our time’ [4]. The Oslo Declaration refers to human
rights several times, accepting that ‘health is a funda-
mental right of every human being’ and, in line with
legal scholarship, that ‘life is the most fundamental of
human rights, and that life and health are the most
precious assets’ [4]. South Africa has also harnessed
its moral power, its own struggle for democracy, its
commitment to the promotion of human rights, and
its multilateral focus to leverage its own sovereignty
and that of weaker states, especially with respect to
access to medicines and migration of health profes-
sionals [18,19,23,24]. In particular, the South African
government has championed for increased access to
ARV drugs to provide universal treatment to all HIV-
positive people [25]. The role of human rights was
emphasized by a non-state actor:
When we were fighting the pharmaceutical (indus-
try) in 1998, we used the human rights argument
strongly . . . (because) . . . we knew as a new democ-
racy emerging out of apartheid . . . (with) the strong
moral presence of President Mandela . . . nobody
would want to be seen to be resisting the intent of
this new government to make medicines affordable
to the people who have been marginalized.
Despite strong views on human rights, the politics of
solidarity and sovereignty has interfered with inter-
national policy. South Africa, like many other African
countries, places importance on autonomy and inde-
pendence, which may overshadow the importance of
human rights in the policymaking process [26].
Protecting national sovereignty has led to important
transnational issues, such as sex worker health and
rights, falling by the wayside. A state actor gave the
following example:
We have been pretty silent to HIV related to human
rights failures in Africa on sex worker[s], you know
even though we do well as a country, it doesn’t seem
to be something we need to export.
Content: health in all policies
South Africa uses a Health in All Policies (HiAP)
approach to incorporate health outcomes into non-
health-sector policies [7,27,28]. This represents an
inter-sectoral approach to developing national and sub-
national public policy such that health outcomes are
given full consideration by the non-health sectors.
South Africa’s National Department of Health’s
Strategic Plan aims to ‘prevent disease and reduce its
burden, and promote health through amulti stakeholder
National Health Commission’ [29]. South Africa’s
health-related foreign policy interests are reflected in
the Oslo Ministerial Declaration [4]. Achieving these
aims will require collaboration and participation in a
system of global health governance to ‘influence position
and strengthening policy coherence and coordination’.
A close examination of the contents of the action agenda
highlights the following values:
. . . [there is an] acknowledgement that globalisation
requires new forms of governance in order to ensure
sustainable development, social and economic equity,
justice, peace, and security. It recognises the need for
cooperation and collaboration, a respect for national
sovereignty, a sense of shared responsibility, and the
attributes of transparency, trust, accountability, and fair-
ness. [4]
In order to promote HiAP, South Africa’s public health
experts have participated in various national and global
initiatives that have encouraged policymakers to prior-
itize the health and human rights of disadvantaged
people in their policies. This represents a bid to effec-
tively reorientate global health systems towards the goal
of healthcare equity [21,30–32]. In South Africa, the
negotiation of lower ARV prices and reforms of the
pharmaceutical supply chain have resulted in the
reduction of ARV prices on the global scale. Thus,
South Africa has successfully leveraged its model fight
against HIV/acquired immune deficiency syndrome
(AIDS) and tuberculosis (TB) to promote South–
South collaboration and leadership. For example, a
rapid scaling-up of ART services in South Africa
resulted in a four-fold increase in the number of people
receiving ART services between 2004 and 2011, as
women, men and children gained greater access to
ART [33]. In addition, the number of TB deaths in
South Africa declined from 70,000 in 2009 to fewer
than 40,000 in 2014 [34,35]. This, in turn, has enhanced
the country’s reputation and influence at the global
level, and granted South Africa a more significant
voice in global health governance systems [36–38].
Agenda-setting phase: shaping and determining
the issues of importance
South Africa has participated in various global initia-
tives to raise the profile of health issues of importance
in general, and access to medicines in particular,
within the world of foreign policy development [39–
42]. Nationally, South Africa successfully drew the
attention of the world when it passed a law allowing
cheap generic drugs to be imported to promote uni-
versal access to medicines. In 2001, South Africa
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successfully put access to medicine in the global spot-
light through the Pharmaceutical Manufacturers
Association (PMA) case in which 39 pharmaceutical
companies took the South African government to
court regarding the government’s intention to reform
its Medicines Act [38]. In this case, the South African
government, backed by various civil society organiza-
tions (CSOs) and transnational networks, was instru-
mental in highlighting access to medicines as a global
policy issue [38,42]. The case was followed by various
high-level meetings and processes which kept atten-
tion on the issue and motivated the development and
adoption of the Doha Declaration in 2001, as well as
the health-related flexibilities contained in the Trade-
Related Aspects of Intellectual Property Rights
(TRIPS) agreement. As explained by one state
interviewee:
our access to medicines is centered mostly, mostly to
a large extent, not around politics of getting medi-
cines, maybe a little around infrastructure for
absorption of medicines . . . but largely access to
medicines for developing countries including our-
selves is the cost . . . remember in medicine one of
the biggest factor[s] on the price of medicine is what
they call the ability to pay . . . ability to pay in south
Africa is quite high.
However, the reason why South Africa went for years
without the option of sourcing generics was because
some pharmaceutical companies have managed to
limit generic competition by entering into voluntary
licensing agreements with the majority of Indian gen-
eric manufacturers, and these manufacturers were
unable to export generic medicines to middle-income
countries such as South Africa and Brazil [43].
Furthermore, although Gilead did not patent tenofo-
vir disoproxil fumarate (TDF) in South Africa, it
awarded the licensing agreement to Aspen
Pharmacare and the overall result was that TDF
remained a monopoly (single-source) product
[43,44]. In addition, while experts involved in ARV
price negotiations and forecasting anticipated reduc-
tion in the price of TDF, three major obstacles to
South Africa’s inability to access lower prices were
the ARV tendering process for 2008, legal restrictions
and medicine registration [43,44]. For instance, the
first ARV tender, concluded in 2004, locked the
South African government into a 3 year agreement
with manufacturers. In addition, certain bidding
clauses, such as the need for bidders to submit a
copy of the actual patent or an agreement with the
patent holder, were potentially highly restrictive.
Regarding medicine registration, despite affordable,
quality-assured, generic versions of TDF becoming
available in 2006, the medicine took several more
years to be registered because of the complexity of
two pharmaceutical companies owning different
patents [43,44].
Globally, South Africa, as part of the Oslo Group,
drove the development of the first three resolutions
for the integration of global health into foreign pol-
icy at the UNGA; namely, Resolutions A/63/33,
2008; A/64/108, 2009 and A/65/95, 2010 [45].
These resolutions afford more attention to global
health in the development of a number of nations’
foreign policies. Several countries have already
launched national global health strategies – such as
Switzerland (2006), the UK (2008), Norway and
Japan (2010) and Sweden (2011), as well as the
European Union. These resolutions were followed
by various high-level meetings and processes that
kept the world’s attention on these issues and led
to the adoption of various further resolutions and
reports by the United Nations Secretary General
(UNSG) on the integration of global health into
foreign policy at the UNGA itself.
Policy development process: multilevel and
multisectoral process
In South Africa, the process of integrating health into
foreign policy within a multisectoral structure was
directed by two main principles: ‘inclusiveness’ and
‘human-rights-centredness’ [25,30,32,46]. For exam-
ple, during the development of various aspects of
South Africa’s National Strategic Plan for HIV/AIDS
(the NSP), the broad consultation and consensus-
building process ensured that various important sta-
keholders were included as actors in the policymak-
ing phase [46]. The literature highlights the
importance of mobilizing various stakeholders and
community responses in order to facilitate improved
access to health and healthcare services in South
Africa [27,30,47,48]. Experience has shown the
importance of rooting HIV projects at the commu-
nity level, and then scaling these activities up to
include civil society, business and public health initia-
tives. This bottom–up approach has led to consider-
able innovation and expansion with regard to HIV-
prevention endeavours in South Africa. For example,
the Global Fund has seen fit to support one of the
largest and most innovative HIV prevention pro-
grammes in the world, in Khayelitsha (in South
Africa’s Western Cape province) [25,48].
Transferring these local innovations to national pro-
grammes and ensuring sustainability remains a chal-
lenge to South African initiatives. However, South
African initiatives may be hamstrung by the lack of
communication between key stakeholders from civil
society, the private sector and academia.
Furthermore, South African policymakers have been
criticized by CSOs for being ‘too accommodating’ of
the needs of the developed countries during TRIPS
negotiations [49].
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Policy implementation process: politics and
power in context
Even though South Africa has participated in various
forums for the integration of health into foreign
policy, especially to improve access to medicines in
South Africa, the country has faced many challenges
with regard to the implementation of HIV/AIDS pol-
icy [50–52]. At the national level, these challenges are
related to the sheer content, as well as to power
struggles between different levels of government, the
sluggish development of programme infrastructure,
the lack of global experience among policy entrepre-
neurs and a lack of necessary systems. As outlined by
one of state actor:
You can develop a policy but there is a also capacity
to implement the policy . . . the other thing is imple-
mentation demands that you have systems in place,
your systems from regulatory, patent protection,
warehousing, those are not easy things.
While the Foreign Policy and Global Health (FPGH)
initiative and its Oslo Ministerial Declaration gained
prominence by reflecting the rise of health as a for-
eign policy issue, the ultimate impact of the FPGH
appears limited [51,52]. One of the criticisms of the
FPGH was that it lacked a formal coordinating struc-
ture or permanent secretariat to manage the imple-
mentation of the action points on its agenda. The
grey literature seems to suggest that the Oslo Group
was based on personal links and common interests
between the Ministers of Health and Foreign Policy
[51]. Now that most of the original ministers who
were signatories of the Oslo Declaration (including
Dr Dlamini-Zuma) are no longer in power, there has
been a distinct decline in South Africa’s investment in
the FPGH. Furthermore, there has been a lack of
visible implementation of the Oslo Declaration at
the national level. Nevertheless, while it is clear that
the Oslo Declaration was not the catalyst for the
recent rise in global interest in health and foreign
policy, it seems undeniable that it inspired the more
effective UN Resolution A/64/108 on global health
and foreign policy [51].
Actors: managing diversity of health partnerships
in GHD
In South Africa, the integration of health into foreign
policy has been driven by a diverse array of health
partnerships working in collaboration with the gov-
ernment [25,27,30,35,46,48]. For example, inspired by
their new constitution, South African CSOs (and the
Treatment Action Campaign in particular) demanded
that the South African government introduce a
national programme for the prevention of mother-
to-child transmission (PMTCT) of HIV [30]. The
government argued that it could not implement
PMTCT due to the price of drugs such as azidothy-
midine (AZT). However, the Treatment Action
Campaign (TAC) used the South African constitution
to argue that people’s right to health should take
precedence over the profit margin of international
pharmaceutical companies. This case serves as an
example of CSOs’ ability to use the law and governing
institutions to create space for policy reform. Such
cases ultimately resulted in the integration of local
public health issues (such as access to ARVs) into
foreign policy debates.
The literature reviewed for this study demonstrates
the importance of partnerships at the community
level in the bid to improve access to ARVs, and to
successfully integrate health issues into foreign policy
[42,48]. For example, the TAC built on the success of
its fluconazole campaign and mobilized local South
Africans on the ground and all of its global contacts
(in particular its close ally, Doctors Without Borders)
to prove to the South African government that treat-
ing HIV/AIDS with cheap generic drugs was cost-
effective and could even be achieved in areas with
limited health facilities in resource-poor settings [48].
Although, ultimately, the South African government
would not issue compulsory licences for medicines,
the TAC-driven pilot programme in Khayelitsha
proved to be a great success. Brazil subsequently
offered to assist South Africa, through technology
transfer, to establish a South African state-owned
pharmaceutical plant. However, the South African
government eventually negotiated with global phar-
maceutical companies to obtain the technology trans-
fer necessary to produce cheap generics for South
Africa through the private sector, such as Aspen
Pharmacare.
The literature reviewed for this study shows that
the only way to effectively respond to the AIDS epi-
demic is by involving all sectors of society, including
business. The South African business sector recog-
nizes that engaging in the HIV/AIDS response is part
of their corporate and social responsibility [15].
Three companies in South Africa – Anglo
American, BHP Billiton and Eskom – have been
providing their HIV-positive employees with ART.
This has shown that partnerships between industry,
labour, government, communities and civil society
represent the most promising approach to effectively
addressing the global AIDS epidemic.
By the same token, the literature also demonstrates
how other developing countries such as Brazil, India
and Thailand have been successful in influencing
HIV/AIDS policy reforms in South Africa as ‘signifi-
cant others’ in various partnerships [38,42,46,53]. For
example, the PMA case of 2001 harnessed strong
leadership from the Brazilian government, strong
activist mobilization and a number of other factors,
and laid the groundwork for the Doha Declaration of
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2001. The Declaration clarified much of the legal
uncertainty that had existed around the TRIPS agree-
ment, particularly with regard to flexibility in domes-
tic laws designed to safeguard public health and the
affordability of drugs. In the Declaration, the World
Trade Organization (WTO) member countries state
the following:
We affirm that the agreement [TRIPS] can and
should be interpreted and implemented in a manner
supportive of WTO members’ right to protect public
health and, in particular, promote access to medi-
cines for all. [54]
Furthermore, the literature shows that transnational
networks have successfully employed the strategy of
‘issue linkage’ to assist South Africa in reforming its
policy on HIV/AIDS [30,38,42]. For example, in
February 1998, 39 (mostly multinational) pharmaceu-
tical manufacturers filed a suit against the South
African government, alleging that the Medicines and
Related Substances Control Amendment Act No. 90
of 1997 (known as ‘the Amendment Act’) violated
both TRIPS and the South African constitution [30].
By the time the case finally reached the courtroom in
May 2000, the drug companies could no longer rely
on the support of their home governments.
In addition, the literature demonstrates that even
though South Africa is an upper middle-income
country, it continues to receive significant funding
support from the Global Fund and the US
President’s Emergency Plan for AIDS Relief
(PEPFAR) owing to its high disease burden. South
Africa’s financial contribution to the HIV/AIDS pro-
gramme has increased from 76% in 2011 to 80% in
2013 [55]. The second highest HIV contribution over
the same period was made by the US government,
although this contribution decreased from 22% (of
the total) in 2011 to 17% in 2013. The Global Fund’s
contribution to HIV- and TB-related causes in South
Africa rose from 1% of the total in 2011 to 3% in
2013 owing to initial delays in the start-up of the
Single Stream Funding grant. Declining donor fund-
ing will be detrimental to health development in
South Africa since the government amended its
HIV treatment threshold to a CD4 cell count of
500 cells/mm3 in May 2016 and committed to reach-
ing its 90–90–90 targets of the Joint UN Programme
on HIV/AIDS, both of which are bold and ambitious
steps that can only be accomplished with significant
resource input.
Despite assurances by the US Embassy in Pretoria
that there is ‘every expectation that funding levels will
continue’, there is growing anticipation that this
assistance will decline and ultimately flatline [55].
Although relatively little US funding is used for
ARV purchases or service delivery, the vast majority
is earmarked for essential training and technical
assistance. For example, the US government, through
its PEPFAR programme, worked in partnership with
South Africa’s national, provincial and local govern-
ments, non-governmental and faith-based organiza-
tions, academics and the private sector to improve
various life-saving HIV/AIDS prevention, care and
treatment services across South Africa. Some of the
interviewees in this study supported the view that
development health assistance is the driving force
behind South Africa’s many recent achievements in
the area of HIV/AIDS. As one interviewee stated:
. . . for example to be quite honest if we didn’t have
PEPFAR support in South Africa, we wouldn’t have
made gains that we have made right . . . we would
have made gains for sure because we have put our
own money as well, . . .
To ensure access to medicines, especially ARVs, sta-
keholders need to operate effectively in complex,
interdependent networks of organizations and sys-
tems across the public, private and non-profit sectors
[27,56,57].
Indications of impact
There is no global health strategy or policy in South
Africa which enumerates a set of actions against
which indicators will be developed and progress mea-
sured. However, issues of global health are reflected
in South Africa’s ‘National Development Plan: Vision
2030’ and the Department of Health’s ‘Strategic Plan:
2014–2019’, which have set out strategic objectives
and sets of actions against which indicators will be
assessed and progress measured [21,58].
Furthermore, South Africa’s global health priorities
are reflected in the Oslo Declaration and various
BRICS Ministerial Declarations on health. The review
of the literature suggests that South Africa’s impact
could be categorized into six areas, namely: norma-
tive change, informal norms and power, establish-
ment of new institutions, health impact, market
impact and financial impact.
This study suggests that the main reason for South
Africa’s positive impact on global health has been its
commitment to health as a human right, as enshrined
in the South African Constitution, the Bill of Rights
and the National Health Act of 2003 [21,23,31]. This
positive impact has manifested as a number of neces-
sary normative changes, having been shaped in both
law (national and international) and international
relations. Furthermore, South Africa’s tenets of
human dignity, equity, the advancement of human
rights and the promotion of individual freedoms have
advanced the nation’s reputation as a respected global
player [27,50].
With respect to informal norms and power, var-
ious South African political and technical experts
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have been invited to chair or participate in numerous
technical and advisory committees established by
multilateral organizations. As one of the state inter-
viewees in this study explained:
WHO for example when they invite people from the
[SA] Department to attend their meeting to give
strategic direction, then you know it means they
value your input because you have done a good
work at home or that you have a lot of influence
by the people . . . many of the reasons they ask me to
chair for example, it’s is not because as an individual,
because they know if South Africa then adopt this
thing, the rest will follow . . . You will see now
because DG has been chairing EB, you will see that
South Africa’s esteem in the world have gone up.
With respect to the establishment of institutions, this
study suggests that South Africa’s overseas develop-
ment cooperation has recently been further strength-
ened through the establishment of the development-
focused South African Development Partnership
Agency (SADPA) and the Department of Health’s
Development Cooperation Unit (DCU) [49,58,59].
This implies that South Africa’s global development
engagements could be even further be strengthened
by the establishment of a partnership between the
DCU and SADPA. However, the SADPA’s activities
in global health have not been prioritized or governed
by any broad strategy. Several interviewees have high-
lighted the role played by South Africa in develop-
ment cooperation:
The other way to measure the success of global
health diplomacy is the extent to which people call
South Africa to assist them, when there is a disaster
so then you know that people think that . . . help
them.
With respect to health impact, this article shows that
the integration of health into South Africa’s foreign
policy, along with the reform of various policy instru-
ments, led to a decline in the number of AIDS deaths
in South Africa from 320,000 in 2010 to 140,000 in
2014. Furthermore, the number of mother-to-child
HIV transmissions dropped from 70,000 in 2004 to
under 7000 in 2015 [60]. Thus, South Africa has been
able to significantly improve the average life expec-
tancy of its people in recent years [58].
With respect to market impact, this study shows
that South Africa has successfully utilized certain
TRIPS flexibilities, such as parallel importation, to
bring about certain reforms (e.g. those to the
Amendment Act of 1997) that have led to the provi-
sion of a sustainable supply of essential medicines
[61,62]. South African has now established mechan-
isms by which to implement all of the provisions
contained in the WTO’s TRIPS flexibilities for public
health. As South Africa’s Minister of Trade and
Industry, Dr Davies, emphasized during a WTO
meeting in April 2016:
First, following many delays, we have recently rati-
fied the WTO Paragraph 6 mechanism that allows
the issuance of compulsory licenses for export of
medicines to countries that lack pharmaceutical
manufacturing capacity. [63]
Through its Competition Law, South African govern-
ment has been able to increase its local generic com-
petition when several of its pharmaceutical
manufacturers entered into voluntary licensing
arrangements [61]. For example, South African firm
Aspen Pharmacare has participated in several joint
ventures with multinationals to manufacture and dis-
tribute branded and generic pharmaceuticals for both
South African and African markets [64].
With respect to financial impact, this study sug-
gests that the threat of compulsory licensing aided
South Africa in its price negotiations with pharma-
ceutical companies, and was also successfully har-
nessed to obtain significant discounts from a
number of brand manufacturers [65]. Furthermore,
by reforming its drug tendering systems, South Africa
has saved millions of dollars that can be better spent
on expanding the nation’s treatment programmes.
South Africa’s overall ARV expenditure fell by 53%
between 2011 and 2012, generating estimated savings
of about $685 million [66,67].
Discussion
This study has illustrated the social, political, eco-
nomic and institutional preconditions (and the com-
plex interplay among them) that are necessary for
successful GHD processes. It has also shown the
extent to which international responses and colla-
boration can contribute to the efficacy of these pro-
cesses. For example, evidence presented in this article
shows that South Africa’s domestic HIV/AIDS con-
stituencies, in partnership with the global advocacy
movement, were influential in mobilizing support for
universal access to ART on a global scale [68,69].
It has been demonstrated that political actors such
as civil society, transnational networks, the global
private sector, philanthropic foundations, ‘think
tanks’ and a much wider range of countries than
ever before now possess the necessary means for
constructive participation in global health governance
[69,70]. This article illuminates the significant role of
health partnerships in facilitating access to medicines
(especially ARVs) in South Africa – a country with
limited public resources and therefore a particularly
acute interest in the potential health benefits of suc-
cessful GHD processes.
This article has confirmed the findings of other
studies which found that in South Africa, integration
of health into foreign policy was informed by a series
of ‘focused events’ (such as the 13th International
AIDS Conference, the Global March for HIV/AIDS
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Treatment, the PMA case in 2001, the Hazel Tau case
and the Oslo Declaration), which led to ‘a turning
point in acceptance of the right of access to treatment
for people in Africa and other developing countries’
and health as a foreign policy issue [69,70]. Problems
that have had to be addressed include South Africa’s
historical context of democratization, oppression and
apartheid, acute political and social inequalities, and
the socio-economic challenges of severe poverty and
extreme inequality in living standards, income and
opportunity. Based on these challenges, South Africa
has worked towards a rule-based multilateral system
that is fair, balanced and inclusive, and the establish-
ment of a new discourse focused on the significance
of health for development and economic growth [69].
Multilateralism can therefore be seen as a key ingre-
dient of positive change, even if many multilateral
focused events have not been taken far enough to be
significantly influential. Our study further supports
previous studies advocating that the PMA case of
2001 was instrumental in laying the foundations for
the negotiations and ultimate adoption of the Doha
Declaration of 2001 [69].
This study has also confirmed suggestions in the
literature that the integration of health into South
African foreign policy has been made possible
through interactions between domestic and interna-
tional state and non-state actors [70,71]. South Africa
now has the means to participate in global health
governance, and there is a clear shift of power and a
trend towards flexible alliance building in this area,
indicative of a departure from Western dominance
[72,73]. The South African health activism commu-
nity, in consultation with transnational activism net-
works and ‘significant others’ such as the Brazilian
government (‘policy community’), has advocated for
broader access to affordable ARVs and healthcare
services. Illustrative of their growing power, these
national and global AIDS movements have been
able to provide high-quality expertise, conduct
research, provide policy analyses and engage in advo-
cacy, as was the case during the PMA case in South
Africa during 2001 and the Khayelitsha pilot project
[74]. This Khayelitsha pilot project has highlighted
the importance of community mobilization and inno-
vation in facilitating scale-up projects for HIV pre-
vention in South Africa.
There is a substantial growth of discursive and
resource-based power in South Africa, exemplified
by the country’s involvement in alliances such as
BRICS and IBSA. The IBSA Facility Fund and
BRICS Bank are likely to play a major role in new
models of global health governance and financing
[75–77]. For example, the IBSA Facility Fund, with
US $3 million targeted annually for South–South
development, has been a key in driving the change
of roles in South–South cooperation. Thus, as with
many other traditional structures, the Organisation
for Economic Co-operation and Development’s
(OECD’s) Development Assistance Committee
model of dividing the world into ‘donors’ and ‘reci-
pients’ or ‘subjects’ and ‘objects’ of development is
losing relevance. Once again, the need becomes
apparent for a new and a more systemic way of
understanding the interface of health, development
and wealth on a global scale, including new structures
and novel solutions to twenty-first-century
challenges.
The HIV/AIDS epidemic was clearly a key turning
point or ‘cosmopolitan moment’ in South Africa’s
approach to health; this was the factor that led to
concrete government action to address global health
issues [69,74]. In particular, reducing the cost of ART
was the most important motivation for active engage-
ment in GHD. The South African government is
justifiably worried about the 3.4 million South
Africans who were on ART by end of 2015, and an
added concern is the affordability of second line and
third line ARVs as more people develop resistance to
first line drugs [69,74]. Furthermore, South Africa is
worried about keeping them on treatment and thus
increasing the burden with respect to the provision of
medicines to all people living with HIV.
The policy stream was achieved through the devel-
opment of a series of breakthrough policy reforms
such as provision of free ARV medicines to people
eligible for treatment (based on the 2010 WHO ART
guidelines), reformation of drug tendering systems
and the launch of the National Health Insurance
policy. The policy stream was established by ensuring
that HIV/AIDS treatment is among the core issues to
be addressed and furthered by the Zuma administra-
tion. The South African national ART programme
has already been given partial credit for the signifi-
cant increase in South Africa’s life expectancy.
While diplomacy has traditionally been seen as the
preserve of the political elite, this study has demon-
strated that South Africa’s non-state actors such as
the health activist community, academia and the pri-
vate sector have successfully managed to leverage
their organizational and legal resources to achieve
wider access to affordable ARVs and healthcare ser-
vices in South Africa. More broadly, successful use of
‘transnational issue networks’ has been an important
aspect of South African engagements in GHD [72,73].
Notwithstanding these observations, this study has
confirmed the results of other research that GHD
policy processes are still subject to traditional political
power dynamics [78,79].
Our study illustrates that the cross-sectoral nat-
ure of health policy problems is developing accord-
ing to two trends. The first trend,
‘transgovernmentalism’ [80], is the development of
policies by international networks of bureaucrats,
GLOBAL HEALTH ACTION 9
lawyers, agencies and so on. The changing roles of
health and foreign ministries are accompanied by a
loss of autonomy. The second trend follows the
increased involvement of international, private and
transnational actors in the formation of foreign
policies that integrate public health. Health and
foreign ministries not only are losing authority to
other ministries, but also need to consider and
cooperate with non-state actors [72,73]. This study
further demonstrated a tendency towards ‘denatio-
nalization’. Transnational actors such as Doctors
Without Borders, Oxfam and the Gates
Foundation are a force to be reckoned with in
international politics. Transnational actors are
influential in global health debates, and in the case
of South Africa, most notably in the case of the
Khayelitsha project, they were involved in the
development and implementation of health policies.
Conclusion
In this paper, we use four consecutive steps to illus-
trate how public health is integrated into foreign
policy in South Africa. First, South Africa is still
focused inwards, and international engagement is
driven by its domestic challenges (such as the burden
of HIV/AIDS and TB). Secondly, owing to the trans-
boundary nature of diseases, South Africa has begun
to take an effective regional and global leadership role
in GHD, especially in the areas of HIV/AIDS, TB and
malaria control. Access to medicines and treatments
for all individuals may be a potential entry point for
South African engagement in GHD.
Thirdly, in the field of GHD, we show that trans-
national networks and/or actors may influence a gov-
ernment’s decision making by providing information
and moving issues up the agenda. While transna-
tional networks and/or actors have been influential
in global health debates, GHD is still a state-centric
process. Fourthly, we argue that GHD analyses need
to incorporate non-state actors into their frameworks.
Therefore, empirical research is needed that describes
these changes and their impact on the integration of
health into foreign policy.
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